Form S-8 Moderna, Inc.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St futures muted as investors monitor US-Iran negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Moderna (MRNA) downgraded as HSBC skeptical on medium term INT Phase 3 data readouts
February 26, 2024 9:33 AM ESTHSBC analysts cut Moderna (NASDAQ: MRNA) to Reduce from Hold in a note Monday, raising the price target to $86 from $75 per share.
The firm said Moderna's outlook for 2024 is underpinned by prospects for its COVID-19 vaccine revenue and RSV launch. They note there are two... More
